Explore the complex pathophysiology of bronchiectasis, including airway infection, chronic inflammation, and mucociliary dysfunction. Learn how genomic approaches, proteomics, and epigenomics offer new insights into disease endotypes and patient stratification for improved therapies. Discover the role of trained innate immunity in complementing current models.
Aspergillus-associated disorders in bronchiectasis, based on data from the EMBARC Registry. ABPA, AS, and AB: Impact on disease severity, diagnostic criteria efficacy, etc.
Marked differences in peripheral blood immune cell gene expression were observed between bronchiectasis patients and healthy controls.
Transcriptomic changes were associated with disease severity and airway inflammation identifying potential novel biomarkers and therapeutic targets.
Video completo de la Primera Edición de REPRIMARIA de 8 del Mayo 2024
Some patients develop post-COVID organizing pneumonia (OP), which is responsiveto treatment with corticosteroids.
The efficacy and safety of mepolizumab in patients with COPD has been investigated in two placebo-controlled Phase 3 trials, METREX and METREO, and theongoing MATINEE trial.
This article examines exacerbations of COPD, emphasizing the need for identifying distinct etioendophenotypes to develop targeted therapies and improve current modest outcomes.
Durante la jornada RESPrimaria se destacó la importancia de la prevención y el diagnóstico precoz en la lucha contra estas patologías.
Más de 900 sanitarios se reunirán de forma presencial y online, este miércoles en Barcelona, para mejorar la prevención y el tratamiento de las
patologías respiratorias.
Treatment with LABA/LAMA is recommended in GOLD B patients. We hypothesized that triple therapy (LABA/LAMA/ICS) will be superior to LABA/LAMA in achieving and maintaining clinical control
